|Videos|April 10, 2020
Weekly Webinar Series Part 5: Managing Lung Cancer Patients Through the COVID-19 Pandemic
Advertisement
Episodes in this series
In part 5 of our weekly COVID-19 Webinar Series, Nathan Pennell, MD, PhD; Stephen Liu, MD; Charu Aggarwal, MD, MPH; H. Jack West, MD; with special guest speaker, Miriam A Knoll, MD, DABR; will share the latest updates and insights on the novel coronavirus. The webinar covers key information regarding:
- Evolving radiation strategies in the era of COVID-19
- How recently updated guidelines impact use of radiation
- Management of physician and healthcare worker wellness and stress
- Case-based discussions in COVID-19—positive patients
Advertisement
Related to this article
Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5